首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷

市場調查報告書

商品編碼

1736410

全球臨床前影像市場規模（按模式、應用、最終用戶、地理和預測）

Global Preclinical Imaging Market Size By Modality, By Application, By End-User By Geographic Scope And Forecast

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

臨床前影像市場規模與預測

2024 年臨床前影像市場規模價值為 9.5755 億美元，預計到 2032 年將達到 14.2772 億美元，2026 年至 2032 年的複合年成長率為 5.12%。

臨床前成像是一系列先進的成像技術，用於在人體臨床試驗之前研究動物模型中的生物過程。這些技術包括 MRI、PET、CT 和生物發光成像，使研究人員能夠研究新藥的效果、追蹤疾病發展並評估體內治療反應。臨床前影像在藥物發現和開發中至關重要，因為它使科學家能夠收集有關新療法療效和安全性的關鍵數據、研究藥物動力學並改進測試設計。
隨著人工智慧和機器學習的融入，臨床前成像領域即將迎來重大突破，影像處理和解讀也將得到改進。成像技術的進步有望提高靈敏度和解析度，從而能夠在分子層面上更準確地評估生物過程。
對個體化醫療的日益關注可能會推動定製成像技術的發展，這種技術可以預測個體對藥物的反應，最終改善轉化研究成果並加快人體臨床試驗的進程。

全球臨床前影像市場動態

影響全球臨床前影像市場的關鍵市場動態是：

關鍵市場促進因素

增加藥物研發投入：據美國國立衛生研究院 (NIH) 稱，製藥公司將在 2023 年投資 950 億美元用於研發，比 2020 年成長 32%。 FDA 預測，2021 年至 2023 年間，需要臨床前影像的臨床實驗新藥申請將增加 45%。這種激增是由對更準確、更詳細的治療效果和安全性數據的需求所驅動，正如 PhRMA 的調查結果顯示，目前 78% 的藥物開發項目使用先進的臨床前成像，高於 2020 年的 52%。這種成長凸顯了影像在加快藥物開發、改進測試設計和提高成功率方面發揮的關鍵作用。
慢性病的流行：慢性病的增加推動了對更優臨床前研究工具的需求。世界衛生組織 (WHO) 預計到 2040 年癌症患者數量將增加 60%；美國疾病管制與預防中心 (CDC) 則表示，每 10 個美國人中就有 6 人至少患有一種慢性病。這一成長得益於早期檢測、精準疾病建模和治療方法研發的進步。美國國家癌症實驗室 (美國 National Cancer Lab) 宣布，臨床前影像的資金將增加 89%，到 2023 年將達到 28 億美元，這凸顯了影像在解決這些日益嚴重的健康問題中的關鍵作用。
成像模式的技術進步：成像模式的技術進步顯著提升了臨床前造影成像的能力，從而提高了其在研究中的利用率。醫學影像與技術聯盟估計，2021年至2023年間，影像系統的準確度將提高156%，而多模態方法的準確度將提高234%，從而實現更全面的資料收集。《核子醫學雜誌》報告稱，2023年，人工智慧輔助影像將使研究時間縮短42%，準確度提高68%。

主要問題

影像系統高成本：MRI、PET 和 CT 等先進的臨床前成像技術的購買和維護成本高。這些系統高達數百萬美元，小型研究機構難以負擔，限制了廣泛應用。高昂的成本增加了整體研究成本，並影響了製藥公司的研發預算。這項挑戰，尤其是在新興市場，加劇了人們的負擔能力，並阻礙了市場擴張。
資料管理與儲存問題：臨床前影像會產生大量數據，必須妥善儲存、處理和分析。許多研究機構缺乏管理大型資料集所需的基礎設施和技能，導致資料處理和分析效率低。不良的資料管理會降低研究品質、延誤計劃、增加營運成本，並且是市場拓展的主要障礙，尤其是在影像技術不斷進步的今天。
漫長的開發和商業化週期：開發新的臨床前成像技術並將其推向市場需要大量的研究、開發和監管核准流程。緩慢的發明和商業化速度可能會減緩新成像技術的普及，並限制市場成長。如此漫長的周期也會阻礙投資，尤其是對規模較小的公司而言，因為投資回報可能需要數年時間才能實現，進而影響市場動態。

主要趨勢

多模態成像技術的應用日益廣泛：結合多種顯像模式（例如MRI、PET和CT）的多多模態成像技術的應用日益廣泛，使得在臨床前研究中能夠全面研究生物過程成為可能。這一趨勢有助於更全面、更全面地了解疾病發展和治療效果，從而提高數據品質。人們對這些整合技術的需求日益成長，因為它們能夠在單次實驗中收集到更可靠、更多樣化的數據，從而提高研究效率。
向非侵入性成像方法的轉變：非侵入性成像技術因其能夠在不損害動物模型的情況下追蹤疾病進展而日益普及。光學成像和核磁共振成像等技術可以進行長期反覆觀察，為研究人員提供寶貴的縱向數據。這種向非侵入性技術的轉變推動了對先進的臨床前成像技術的需求，這些技術既能減少倫理擔憂，又能提高實驗數據的品質。
分子影像技術的發展：分子影像技術能夠洞察細胞和分子過程，在臨床前研究中的重要性日益凸顯。它使研究人員能夠在分子層面上研究疾病通路，從而實現更早的診斷和更精準的標靶治療。隨著個人化醫療的加速發展，分子影像技術在標靶藥物研發中發揮關鍵作用，因此其在臨床前研究中的應用日益廣泛，推動了市場的成長。

Preclinical imaging is a collection of advanced imaging techniques used to examine biological processes in animal models before human clinical trials. These techniques, which include MRI, PET, CT, and bioluminescence imaging, enable researchers to study the effects of novel medications, follow disease development, and assess therapy responses in vivo. Preclinical imaging is important in drug discovery and development because it allows scientists to collect key data on the efficacy and safety of new treatments, as well as examine pharmacokinetics and improve study designs.
Preclinical imaging is poised for substantial breakthroughs with the incorporation of artificial intelligence and machine learning to improve picture processing and interpretation. As imaging technologies advance, we should expect increased sensitivity and resolution, allowing for more exact assessments of biological processes at the molecular level.
The increased emphasis on customized medicine is likely to stimulate the development of tailored imaging techniques capable of predicting individual responses to medicines, ultimately enhancing translational research outcomes and expediting the journey to human clinical trials.

Global Preclinical Imaging Market Dynamics

The key market dynamics that are shaping the global preclinical imaging market include:

Key Market Drivers:

Rising Investment in Pharmaceutical R&D: Rising investment in pharmaceutical R&D is fueling robust growth in the preclinical imaging market, with pharmaceutical companies investing USD 95 Billion in R&D in 2023, up 32% from 2020, according to the NIH. The FDA also forecasts a 45% increase in investigational new medication applications that need preclinical imaging between 2021 and 2023. This spike is being driven by the demand for more precise, in-depth data on therapeutic efficacy and safety, as indicated by PhRMA's findings that 78% of drug development programs currently use advanced preclinical imaging, up from 52% in 2020. This growth underlines imaging's critical role in expediting drug development, refining study designs, and increasing success rates.
Growing Prevalence of Chronic Diseases: The increasing frequency of chronic diseases is driving the need for better preclinical research tools. Cancer cases are expected to climb by 60% by 2040, according to the WHO, and 6 out of 10 Americans already have at least one chronic ailment, according to the CDC, resulting in a 67% increase in preclinical research since 2021. This increase is motivated by the need for early identification, precise disease modeling, and improved treatment development. The National Cancer Institute's 89% increase in funding for preclinical imaging, totaling $2.8 billion in 2023, emphasizes the critical significance of imaging in addressing these growing health concerns.
Technological Advancements in Imaging Modalities: Technological advancements in imaging modalities are greatly improving the capabilities of preclinical imaging, resulting in its increased use in research. The Medical Imaging and Technology Alliance estimated that imaging system precision improved by 156% between 2021 and 2023, while multimodal approaches increased by 234%, allowing for more comprehensive data collection, according to the European Society of Molecular Imaging. According to the Journal of Nuclear Medicine, AI-enhanced imaging will decrease research durations by 42% and improve accuracy by 68% in 2023.

Key Challenges:

High Cost of Imaging Systems: Advanced preclinical imaging technologies, including as MRI, PET, and CT, are expensive to purchase and maintain. These systems can cost millions of dollars, making them unavailable to smaller research institutes and limiting their broad use. The high costs increase overall research expenses, hurting pharmaceutical companies' R&D budgets. This challenge stifles market expansion since affordability becomes a hurdle, particularly in emerging markets.
Data Management and Storage Issues: Preclinical imaging produces a large amount of data, which must be appropriately saved, handled, and analyzed. Many institutions lack the necessary infrastructure and skills to manage massive datasets, resulting in inefficiencies in data processing and analysis. Poor data management can jeopardize research quality, delay projects, and raise operational expenses, posing a substantial impediment to market expansion, especially as imaging technologies advance.
Long Development and Commercialization Cycles: Creating new preclinical imaging technologies and bringing them to market requires extensive research, development, and regulatory approval processes. The slow rate of invention and commercialization might cause delays in the adoption of new imaging technologies, limiting market growth. This protracted cycle also discourages investment, particularly from smaller enterprises, because the return on investment might take years to realize, influencing market dynamics.

Key Trends:

Increasing Use of Multimodal Imaging Techniques: The increasing use of multimodal imaging techniques, which combine several imaging modalities such as MRI, PET, and CT, allows for complete investigation of biological processes in preclinical studies. This trend improves data quality by providing a more complete and comprehensive understanding of illness development and treatment efficacy. The capacity to collect more robust and diversified data in a single experiment is boosting demand for these integrated technologies, which increase research efficiency.
Shift to Non-invasive Imaging Methods: Non-invasive imaging techniques are gaining popularity due to their ability to track disease progression without causing harm to the animal model. Methods such as optical imaging and MRI allow for repeated observations throughout time, giving researchers valuable longitudinal data. This shift toward non-invasive techniques is increasing demand for sophisticated preclinical imaging technologies, which lessen ethical issues while also improving experimental data quality.
Growth in Molecular Imaging: Molecular imaging, which allows for the viewing of cellular and molecular processes, is becoming more important in preclinical research. It enables researchers to investigate disease pathways at the molecular level, resulting in earlier identification and more precise treatment targeting. As personalized medicine gains pace, molecular imaging plays an important role in creating targeted medicines, increasing usage in preclinical investigations, and propelling market growth.

Global Preclinical Imaging Market Regional Analysis

Here is a more detailed regional analysis of the global preclinical imaging market:

North America:

North America's dominance in the preclinical imaging market is primarily due to its strong pharmaceutical and biotechnology sectors. The United States accounts for about half of the global market, owing to considerable investments in research and infrastructure. As of 2023, the National Institutes of Health (NIH) reported a 156% growth in preclinical imaging spending, totaling USD 12.7 Billion. This expansion is being driven by an increasing need for improved imaging technologies in drug discovery and development, notably with the rise of customized medicine.
Pharmaceutical companies have increasingly utilized preclinical imaging, with the United States Food and Drug Administration (FDA) reporting an 89% increase in companies adopting these technologies between 2021 and 2023. Canada's biotechnology sector also contributes, with preclinical imaging expenditures increasing by 178%, reinforcing North America's leading spot.
Investment in research and development (R&D) is critical to boosting North America's preclinical imaging market. The National Science Foundation reports that between 2020 and 2023, private-sector R&D spending on imaging increased by 234%, reaching USD 18.5 Billion. This is supplemented by a predicted 67% increase in federal funding for preclinical research by 2026. Technological developments have also been important drivers, with institutions purchasing 45% more preclinical imaging equipment in 2023 compared to 2021. Such infrastructure expansion has resulted in speedier drug development schedules, with the FDA reporting a 145% increase in medication applications that include preclinical imaging data. This incorporation of imaging technology into drug discovery speeds up the research process and increases success rates, consolidating North America's market leadership.

Asia Pacific:

The Asia Pacific region is experiencing tremendous expansion in the preclinical imaging market, making it the fastest-growing market globally. Between 2021 and 2023, the market grew by 189% to USD 5.8 Billion, owing to increased investments in healthcare infrastructure and technology improvements. China, Japan, and India have greatly increased funding for preclinical research. China's investment alone increased by 234% to ¥45.6 billion (USD 7.1 Billion) during this period. Government initiatives, such as public-private partnerships and collaborations between academic institutions and pharmaceutical businesses, have also increased, adding to market growth. The expansion of preclinical imaging facilities in South Korea and Australia demonstrates the region's growing commitment to complex research capabilities, establishing Asia Pacific as a focus for medical imaging innovation.
Population growth and increased healthcare spending are also propelling Asia Pacific's preclinical imaging market. As the middle class grows and discretionary income improves, healthcare spending in the region climbed by 89% between 2021 and 2023. The World Bank anticipates that by 2025, 45% of the region's population will have access to advanced healthcare services, greatly increasing demand for breakthrough medical technology such as preclinical imaging. Rising research efforts and government-sponsored collaborations are creating a favorable atmosphere for preclinical imaging improvements, hastening expansion in the region.

Global Preclinical Imaging Market: Segmentation Analysis

The Global Preclinical Imaging Market is Segmented on the basis of Modality, Application, End-User, And Geography.

Preclinical Imaging Market, By Modality

Magnetic Resonance Imaging
Computed Tomography
Optical Imaging
Ultrasound Imaging

Based on Modality, the market is bifurcated into Magnetic Resonance Imaging, Computed Tomography, Optical Imaging, and Ultrasound Imaging. Magnetic Resonance Imaging (MRI) leads the preclinical imaging market due to its high resolution and non-invasive nature, making it perfect for precise anatomical and functional analyses. The broad use of MRI in neurological and cancer research has cemented its position as the leading technology. Optical Imaging is the fastest expanding segment, thanks to its capacity to deliver real-time molecular imaging with little invasiveness. Its rapid expansion is being driven by increased demand in oncology and cardiovascular research, where early-stage drug discovery necessitates sensitive, real-time imaging of biologic processes.

Preclinical Imaging Market, By Application

Research and Development
Drug Discovery

Based on Application, the market is segmented into Research and Development and Drug Discovery. Drug discovery is the dominant segment in the preclinical imaging market due to its critical role in determining medication efficacy and safety prior to clinical testing. Drug discovery is the most important application because to rising demand for precision medicine and increased pharmaceutical R&D investments. The fastest-growing category is research and development (R&D), which is driven by increased investment in breakthrough technologies and the need for enhanced imaging techniques to hasten the discovery of new medicines, notably in oncology and neurological disorders.

Preclinical Imaging Market, By End-User

Pharmaceutical and Biotechnology Companies
Research Institutes

Based on End-User, the market is segmented into Pharmaceutical and Biotechnology Companies and Research Institutes. Pharmaceuticals and Biotechnology Companies dominate the preclinical imaging market because they make substantial use of imaging technologies in drug development and testing. Their enormous investments in R&D, along with the quest for speedier drug discovery methods, position them as the market leader. Research institutes are the fastest-growing segment, owing to increased government financing and academic-industry cooperation. These institutes are quickly using advanced imaging technologies to support cutting-edge research, including disease models and therapeutic development.

Preclinical Imaging Market, By Geography

North America
Europe
Asia Pacific
Rest of the World
On the basis of Geography, the Global Preclinical Imaging Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the preclinical imaging market thanks to its strong pharmaceutical and biotechnology industries, superior infrastructure, and large R&D investments. The Asia Pacific region is witnessing the quickest growth, owing to rising healthcare spending, increased research activity, and increased awareness of preclinical imaging techniques.

Key Players

The "Global Preclinical Imaging Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bruker Corporation, Siemens A.G., General Electric, TriFoil Imaging, PerkinElmer, Inc., VisualSonics, Inc., Mediso Ltd., Agilent Technologies, MILabs B.V., MR Solutions, and Molecube. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Preclinical Imaging Market Recent Developments
In April 2024, Spectral Instruments Imaging announced the release of Aura 4.5, the most recent version of its in vivo imaging software.
In April 2023, Southern Scientific announced that it will become the new UK distributor for Spectral Instruments Imaging, a leading provider of preclinical in vivo imaging equipment.

1 INTRODUCTION OF GLOBAL PRECLINICAL IMAGING MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PRECLINICAL IMAGING MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities

5 GLOBAL PRECLINICAL IMAGING MARKET, BY MODALITY

5.1 Overview
5.2 Magnetic Resonance Imaging
5.3 Computed Tomography
5.4 Positron Emission Tomography
5.5 Single Photon Emission Computed Tomography
5.6 Optical Imaging
5.7 Ultrasound Imaging

6 GLOBAL PRECLINICAL IMAGING MARKET, BY APPLICATION

6.1 Overview
6.2 Oncology
6.3 Neurology
6.4 Cardiology
6.5 Inflammation
6.6 Infectious Diseases
6.7 Metabolic Diseases

7 GLOBAL PRECLINICAL IMAGING MARKET, BY END-USERS

7.1 Overview
7.2 Pharmaceutical & Biotechnology Companies
7.3 Contract Research Organizations
7.4 Research Institutions & Academic Centers
7.5 Hospitals & Clinics

8 GLOBAL PRECLINICAL IMAGING MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL PRECLINICAL IMAGING MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Bruker Corporation
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Siemens A.G.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 General Electric
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 TriFoil Imaging
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 PerkinElmer, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 VisualSonics Inc. (Fujifilm)
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Mediso Ltd.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Agilent Technologies
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 MILabs B.V.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 MR Solutions
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments